Numis Securities reaffirmed their add rating on shares of Dechra Pharmaceuticals (LON:DPH) in a research report released on Monday morning. They currently have a GBX 2,640 ($36.47) target price on the stock.
Other research analysts also recently issued reports about the company. Jefferies Group upgraded Dechra Pharmaceuticals to a buy rating and lifted their price objective for the stock from GBX 2,221 ($30.69) to GBX 2,631 ($36.35) in a research report on Tuesday, January 30th. Royal Bank of Canada downgraded Dechra Pharmaceuticals to a sector performer rating and boosted their price target for the company from GBX 2,200 ($30.40) to GBX 2,400 ($33.16) in a report on Thursday, February 1st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of GBX 2,121.17 ($29.31).
Dechra Pharmaceuticals (LON DPH) opened at GBX 2,488 ($34.37) on Monday. Dechra Pharmaceuticals has a 12-month low of GBX 1,594 ($22.02) and a 12-month high of GBX 2,538 ($35.06). The stock has a market capitalization of $2,540.00 and a P/E ratio of 5,408.70.
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.